GleamWall
中文EN

TAK TAKEDA PHARMACEUTICAL CO LTD IFRS Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 1395064 · Reporting currency JPY

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY7.5%
TTM net income YoY-25.1%
TTM EPS YoY-26.3%
Revenue 3-yr CAGR8.7%
Net income 3-yr CAGR-22.3%

Margins

Gross margin65.5%
Operating margin7.5%
Net margin2.4%
FCF margin18.7%
EBITDA margin24.1%

Returns

ROE1.5%
ROA0.7%
ROIC (approx.)1.9%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets51.3%
Debt / equity0.65x
Current ratio1.01x
Interest coverage2.49x

Cash quality & payout

Operating cash flow / net income9.80x
Accruals ratio-6.5%
Payout ratio280.3%
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: JPY FY20252025-03-31FY20242024-03-31
Income statement
Revenue4.58T4.26T
Cost of revenue1.58T1.43T
Gross profit3.00T2.84T
R&D expense730.23B729.92B
Operating income342.59B214.07B
Interest expense137.31B119.53B
Pretax income175.08B52.79B
Income tax66.94B-91.41B
Net income107.93B144.07B
EBITDA1.10T942.08B
EPS (basic)68.3692.09
EPS (diluted)67.2391.16
Weighted avg. shares (diluted)1.61B1.58B
Balance sheet
Cash & equivalents385.11B457.80B
Receivables709.47B668.40B
Inventory1.22T1.21T
Current assets2.52T2.56T
PP&E, netmay include right-of-use assets (IFRS)1.97T1.99T
Goodwill5.32T5.41T
Intangibles3.63T4.27T
Total assets14.25T15.11T
Current liabilities2.51T2.31T
Short-term debt548.94B367.25B
Long-term debt3.97T4.48T
Total debt4.52T4.84T
Total liabilities7.31T7.83T
Shareholders' equity6.94T7.27T
Net debt4.13T4.39T
Shares outstanding1.59B1.58B
Cash flow statement
Operating cash flow1.06T716.34B
Capital expenditure200.79B175.42B
Free cash flow856.39B540.92B
Investing cash flow-367.06B-463.86B
Financing cash flow-751.42B-354.42B
Depreciation & amortization761.40B728.00B
Dividends paid302.50B287.19B
Share buybacks51.86B2.33B

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, JPY, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.